Vilanterol/fluticasone furoate inhaled

Dosage Forms & Strengths

vilanterol/fluticasone furoate inhaled

powder for inhalation

• 25mcg/100mcg per actuation
• 25mg/200mcg per actuation
• Ellipta inhaler contains 2 double-foil blister strips, 1 containing fluticasone furoate and the other strip contains vilanterol; after the inhaler is activated, the powder within both blisters is exposed and ready for dispersion

Chronic Obstructive Pulmonary Disease

Indicated for long-term, once-daily, maintenance treatment of airflow obstruction with COPD, including chronic bronchitis and/or emphysema; also approved to reduce COPD exacerbations

25 mcg/100 mcg (1 actuation) inhaled PO qDay

Asthma

Indicated for once-daily treatment of asthma for patients not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta agonist (LABA)

Use prescribe strength (25 mcg/100 mcg or 25 mcg/200 mcg per actuation) once daily via oral inhalation

Dosage Modifications

Hepatic or renal impairment: No dosage adjustment required

Geriatric patients: No dosage adjustment required

Dosing Considerations

Limitations of use: NOT indicated for the relief of acute bronchospasm

Asthma indication

• LABAs (eg, vilanterol) increase the risk of asthma-related death
• Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients
• Therefore, when treating patients with asthma, physicians should only prescribe vilanterol/fluticasone furoate inhaled for patients not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA
• Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (eg, discontinue vilanterol/fluticasone furoate inhaled) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication (eg, inhaled corticosteroid)
• Do not use for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids

Safety and efficacy not established